1. Scrip
  2. >>COVID-19

Coronavirus Update: Pfizer And BioNTech Kick Off COVID-19 Trial

Dose-Escalation Stage To Enrol Up To 360 Subjects

 
• By Scrip Team

The US behemoth and its German partner have said that if their mRNA vaccine proves to be safe and effective, it could  be ready for US distribution by the end of the year.

SC2005_U-Maryland_Trials_1200.jpg
Pfizer/BioNTech have started dosing of their mRNA vaccines • Source: University of Maryland School of Medicine

Pfizer Inc. and BioNTech SE announced the dosing of the first participants in a Phase I/II clinical trial of their COVID-19 vaccine on 5 May. The study is designed to determine the safety, immunogenicity and optimal dose level of four messenger RNA (mRNA) vaccine candidates evaluated in a single, continuous trial.

In its earnings call last week, Pfizer laid out the timeline for developing a COVID-19 vaccine with the goal of getting it to patients as early as the fall

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.